天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

返回ChemicalBook首頁>CAS數(shù)據(jù)庫列表>769169-27-9

769169-27-9

中文名稱 BEGACESTAT
CAS 769169-27-9
分子式 C9H8ClF6NO3S2
分子量 391.74
MOL 文件 769169-27-9.mol
769169-27-9 結(jié)構(gòu)式 769169-27-9 結(jié)構(gòu)式

基本信息

中文別名
5-氯-N-[(1S)-3,3,3-三氟-1-(羥基甲基)-2-(三氟甲基)丙基]-2-噻吩磺酰胺
英文別名
GSI-953
Begacestat
Begacestat(GSI-953)
GSI-953 DISCONTINUED
Begacestat (Synonyms: GSI-953)
5-Chloro-N-[(1S)-3,3,3-trifluoro-1-(hydroxyMethyl)-2-(trifluoroMethyl)propyl]-2-thiophenesulfonaMide
2-Thiophenesulfonamide, 5-chloro-N-[(1S)-3,3,3-trifluoro-1-(hydroxymethyl)-2-(trifluoromethyl)propyl]-
5-Chloro-N-[(1S)-3,3,3-trifluoro-1-(hydroxymethyl)-2- (trifluoromethyl)propyl] thiophene-2-sulfonamide
(2S)-S-(5-chlorothiophen-2-yl)-4,4,4-trifluoro-1-hydroxy-N-Methyl-3-(trifluoroMethyl)butane-2-sulfonaMido

物理化學(xué)性質(zhì)

沸點355℃
密度1.642
閃點169℃
儲存條件2-8°C
溶解度在DMSO中的溶解度≥15mg/mL
酸度系數(shù)(pKa)8.16±0.50(Predicted)
形態(tài)粉末
顏色白色至棕褐色

安全數(shù)據(jù)

WGK Germany3

常見問題列表

生物活性
Begacestat (GSI-953) 是淀粉樣前體蛋白 γ 分泌酶 (gamma-secretase) 的選擇性噻吩磺酰胺抑制劑 (IC50Aβ40=15 nM),有潛力用于阿爾茲海默癥的研究。
靶點

IC50: 15 nM (Aβ 40 ).

體內(nèi)研究

Begacestat (5 mg/kg, p.o. in mice) treatment for 4 h significantly reduces the Aβ 40 and Aβ 42 in brain (37% lowering of brain Aβ 40 and 25% lowering of Aβ 40 observed).
Begacestat (GSI-953: 0, 2.5, 5, or 10 mg/kg, oral gavage, 3 h) results in a dose-dependent reversal of contextual fear conditioning deficits when compound is orally administered 3 h before training. Significant deficits are observed after treatment with 2.5 mg/kg Begacestat, and there is some reversal of this at 5 mg/kg and full reversal at 10 mg/kg compared with vehicle-dosed Tg2576 mice.
A dosage-related trend of slightly lower percentages of SP CD4+ cells in males at all dosages (SP CD4+ cells=~11% in controls compared with ~7% to ~9% in Begacestat-dosed animals) and females at 2000 mg/kg/day (SP CD4+ cells=~10% in controls compared with ~8% in Begacestat-dosed animals) is observed.

Animal Model: Tg2576 mice
Dosage: 0, 2.5, 5, or 10 mg/kg
Administration: Oral gavage for two consecutive days
Result: Resulted in a dose-dependent reversal of contextual fear conditioning deficits when compound is orally administered 3 h before training.
Animal Model: Sprague-Dawley rats
Dosage: 0, 200, 600, or 2000 mg/kg/day for 10 (5 males/group and 5 females at 600 mg/kg/day) or 28 (10/sex/group) consecutive days
Administration: P.O. for 10 (5 males/group and 5 females at 600 mg/kg/day) or 28 (10/sex/group) consecutive days.
Result: A dosage-related trend of slightly lower percentages of SP CD4+ cells in males at all dosages and females at 2000 mg/kg/day was observed.
"769169-27-9" 相關(guān)產(chǎn)品信息